If that is what is happening, I hope that our new board member with all the FDA history can level the playing field and bring some transparency to the situation. The more credible RCPI's case is, the more difficult it will be for the FDA to sit on this. And with the likes of Dr. Mullan and team, I think the folks at the FDA know they are dealing with a very credible organization with some heavy hitters in their fields-- and a product that certainly deserves to be allowed further research.
News 
Market Data 
Discover 
